MiMedx Group (MDXG) opened 2026 with Q1 revenue of US$59.0 million and a basic EPS loss of US$0.07, compared with revenue of US$88.2 million and basic EPS of US$0.05 in Q1 2025. Over the past year, the company has seen trailing twelve month revenue move from US$348.9 million in Q4 2024 to US$389.4 million in Q1 2026, while trailing basic EPS shifted from US$0.29 to US$0.21. This puts the latest quarterly loss against a backdrop of positive earnings over the last four reported quarters as investors weigh how much margin compression is already reflected in the share price.

See our full analysis for MiMedx Group.

With the headline numbers on the table, the next step is to see how this mix of revenue growth, EPS pressure and margin trends lines up with the most common narratives investors rely on when thinking about MiMedx Group.

TTM profits of US$30.7 million vs Q1 loss

• Over the last twelve months MiMedx Group earned net income of US$30.7 million on revenue of US$389.4 million, even though Q1 2026 on its own showed a net loss of US$10.9 million on US$59.0 million of revenue.
• Consensus narrative points to long term earnings potential supported by diversified products and clinical data. However, the recent shift from a profitable trailing year to a quarterly loss highlights how reimbursement changes and spending on sales and trials can feed straight through to net income and test how durable that long term story really is.
  • Analysts reference margin support from factors like manufacturing efficiency and product expansion. The latest trailing net profit margin of 7.9% versus 11.3% a year earlier shows that higher costs or pricing pressure are already visible in the reported numbers.
  • The consensus view highlights chronic disease trends as a tailwind. At the same time, the Q1 loss and lower trailing margin show that even with those demand drivers, the reported earnings line can still move around when reimbursement rules and operating expenses shift.

Margins pressured at 7.9% trailing level

• The trailing net profit margin sits at 7.9%, compared with 11.3% a year earlier, against a backdrop of trailing revenue of US$389.4 million and net income of US$30.7 million.
• Bears focus on the risk that profit margins shrink further, and the move from 11.3% to 7.9% trailing margin already lines up with their concern that reimbursement caps and higher selling and R&D costs could keep profitability under pressure.
  • Bearish commentary notes that margins could move toward 6.4% over time, and the current 7.9% trailing margin already sits between that level and the 11.3% reference point from the prior year.
  • Critics highlight the need for continued investment in Surgical sales teams and clinical trials, and the Q1 2026 net loss of US$10.9 million alongside the lower trailing margin illustrates how that extra spending can weigh on short term earnings.

Skeptics point to the margin slide and Q1 loss as early evidence of their concerns playing out, and you can see how their full argument fits with these figures in the 🐻 MiMedx Group Bear Case.

DCF fair value of 6.19 vs US$3.36 share price

• MiMedx Group shares trade at US$3.36 with a P/E of 16.3x, while the supplied DCF fair value of 6.194789054742692 and an analyst target of 6.67 both sit higher, and the stock also screens as cheaper than a peer P/E average of 40.3x.
• Bullish investors lean on the idea of high forecast earnings growth of about 28.3% a year together with this gap to DCF fair value. The combination of a 16.3x P/E near the 16.1x biotech industry average plus a DCF figure above the current price is what they cite as potential valuation support if those earnings forecasts are met.
  • Supporters contrast the roughly in line P/E with the biotech industry against the much higher peer average of 40.3x, arguing that this relative discount exists even though the trailing twelve months still produced US$30.7 million of net income and positive EPS of US$0.21.
  • Bulls also reference that earnings have grown over the past five years, and match that history with the current spread between US$3.36 and the DCF fair value of 6.194789054742692 as a reason to keep watching the name if the earnings profile resembles those projections.

If you want to see how supporters connect this valuation gap to their optimistic long term story, check out the full bullish case at 🐂 MiMedx Group Bull Case.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for MiMedx Group on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With both risks and rewards in play, the key question is how you see the balance. Move quickly, review the figures, and weigh the 2 key rewards and 1 important warning sign

See What Else Is Out There

MiMedx Group's recent Q1 loss, softer trailing margin of 7.9% vs 11.3%, and margin pressure concerns all point to profits being under strain.

If that earnings pressure makes you cautious, it is worth urgently sizing up companies screened as resilient on profits and volatility through the 76 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.